The global hemostasis valve market size was estimated at USD 174.8 million in 2023 and is projected to grow at a CAGR of 5.8% from 2024 to 2030. The increasing prevalence of cardiovascular diseases, supportive regulatory frameworks, rising geriatric population, and technological advancements are significantly driving the market growth. According to the report published by World Heart Federation in 2023, cardiovascular diseases (CVDs) have a profound global impact, affecting over half a billion people worldwide and resulting in approximately 20.5 million deaths in 2021.This, in turn, drives the demand for diagnostic and therapeutic procedures like angiography and angioplasty, where hemostasis valves are essential to ensure patient safety by controlling blood flow during catheterization procedures.
The growing preference for minimally invasive procedures is another significant factor propelling the market growth. Minimally invasive techniques offer numerous benefits over traditional open surgeries, including reduced pain, shorter hospital stays, faster recovery times, and lower risk of complications. As a result, there is a heightened demand for medical devices that facilitate these procedures. Hemostasis valves are integral to minimally invasive catheter-based interventions, as they enable precise control of blood flow and prevent leakage during the procedure. The shift towards minimally invasive techniques in cardiology and other medical fields drives the adoption of hemostasis valves.
The global demographic landscape is undergoing a notable shift towards aging, driven by declining birth rates and advancements in healthcare that have prolonged life expectancy. According to the World Health Organization (WHO), the number of people aged 60 years and older is expected to double by 2050, reaching approximately 2.1 billion globally. This demographic transition underscores the increasing prevalence of age-related conditions, including cardiovascular diseases (CVDs) among older adults. According to the article published by the American Heart Association in November 2023, heart failure is a widespread and multifaceted cardiovascular condition impacting more than 6.7 million Americans, particularly prevalent among individuals aged 65 and older. The aging population is susceptibility to cardiovascular diseases drive the demand for diagnostic and therapeutic procedures, driving the market growth.
Technological advancements in medical devices are pivotal in driving the market growth. Materials, design, and functionality innovations have developed more effective and reliable hemostasis valves. For instance, using advanced polymers and coatings has improved the durability and biocompatibility of these devices, reducing complications such as thrombosis and infection. In addition, incorporating novel features such as easy-to-use locking mechanisms and enhanced sealing capabilities has increased the efficiency of hemostasis valves in clinical settings. For instance, the WATCHDOG Hemostasis Valve by Boston Scientific Corporation incorporates an innovative cross-slit design to minimize leakage, complemented by an 8F inner lumen that simultaneously accommodates multiple devices. In addition, it includes a thumb rest feature designed for enhanced comfort during procedures. The design elements collectively contribute to reducing blood loss and the risk of air embolism, prioritizing patient safety throughout medi
cal interventions. These technological improvements ensure that procedures are safer and more efficient, boosting the adoption of hemostasis valves.
This product will be delivered within 1-3 business days.
The growing preference for minimally invasive procedures is another significant factor propelling the market growth. Minimally invasive techniques offer numerous benefits over traditional open surgeries, including reduced pain, shorter hospital stays, faster recovery times, and lower risk of complications. As a result, there is a heightened demand for medical devices that facilitate these procedures. Hemostasis valves are integral to minimally invasive catheter-based interventions, as they enable precise control of blood flow and prevent leakage during the procedure. The shift towards minimally invasive techniques in cardiology and other medical fields drives the adoption of hemostasis valves.
The global demographic landscape is undergoing a notable shift towards aging, driven by declining birth rates and advancements in healthcare that have prolonged life expectancy. According to the World Health Organization (WHO), the number of people aged 60 years and older is expected to double by 2050, reaching approximately 2.1 billion globally. This demographic transition underscores the increasing prevalence of age-related conditions, including cardiovascular diseases (CVDs) among older adults. According to the article published by the American Heart Association in November 2023, heart failure is a widespread and multifaceted cardiovascular condition impacting more than 6.7 million Americans, particularly prevalent among individuals aged 65 and older. The aging population is susceptibility to cardiovascular diseases drive the demand for diagnostic and therapeutic procedures, driving the market growth.
Technological advancements in medical devices are pivotal in driving the market growth. Materials, design, and functionality innovations have developed more effective and reliable hemostasis valves. For instance, using advanced polymers and coatings has improved the durability and biocompatibility of these devices, reducing complications such as thrombosis and infection. In addition, incorporating novel features such as easy-to-use locking mechanisms and enhanced sealing capabilities has increased the efficiency of hemostasis valves in clinical settings. For instance, the WATCHDOG Hemostasis Valve by Boston Scientific Corporation incorporates an innovative cross-slit design to minimize leakage, complemented by an 8F inner lumen that simultaneously accommodates multiple devices. In addition, it includes a thumb rest feature designed for enhanced comfort during procedures. The design elements collectively contribute to reducing blood loss and the risk of air embolism, prioritizing patient safety throughout medi
cal interventions. These technological improvements ensure that procedures are safer and more efficient, boosting the adoption of hemostasis valves.
Global Hemostasis Valve Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this report, the publisher has segmented the global hemostasis valve market report based on type, application, end-use, and regions.- Type Outlook (Revenue, USD Million, 2018 - 2030)
- Hemostasis Valve Y- Connectors
- Double Y- Connector Hemostasis Valves
- One- Handed Hemostasis Valves
- Others
- Application Outlook (Revenue, USD Million, 2018 - 2030)
- Angiography
- Angioplasty
- End-use Outlook (Revenue, USD Million, 2018 - 2030)
- Hospitals
- Ambulatory Surgical Centers
- Others
- Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- South Korea
- Australia
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Hemostasis Valve Market Variables, Trends, & Scope
Chapter 4. Hemostasis Valve Market: Type Estimates & Trend Analysis
Chapter 5. Hemostasis Valve Market: Application Estimates & Trend Analysis
Chapter 6. Hemostasis Valve Market: End Use Estimates & Trend Analysis
Chapter 7. Hemostasis Valve Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Boston Scientific Corporation
- Teleflex Incorporated
- Merit Medical Systems
- B. Braun Melsungen AG
- TERUMO CORPORATION
- Abbott
- Argon Medical Devices
- Freudenberg Medical
- SCW Medicath Ltd
- Lepu Medical Technology(Beijing)Co.,Ltd.
- Nipro
- DeRoyal Industries, Inc.
- Antmed Corporation
- Beijing Demax Medical Technology Co
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 110 |
| Published | July 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 174.8 Million |
| Forecasted Market Value ( USD | $ 258.2 Million |
| Compound Annual Growth Rate | 5.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 14 |
